Is Intellia Therapeutics Inc (NTLA) overvalued? · rev $57.9M
Intellia Therapeutics Inc (NTLA) is a biotechnology company listed on US.
This page asks whether Intellia Therapeutics Inc (NTLA) looks expensive on cached numbers — not a short thesis.
Latest reported NTLA revenue for 2024-12-31 was $57.9M. Net income was -$519.0M. Revenue was up 59.6% from 2023-12-31 to 2024-12-31. NTLA currently screens at market cap $1.19B.
NTLA currently screens at market cap $1.19B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next NTLA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the NTLA stock page for the full model, not this heading.
Not investment advice.